Anebulo Pharmaceuticals (ANEB)

• Market cap: $106M
• 1 day: -1.89%
• 5 days: -3.36%
• 1 month: 12.12%
• 3 months: -4.07%
• 6 months: 125.22%
• Year to date: 63.92%
• 1 year: 37.04%
• 5 years: -63.52%
• 10 years: -63.52%
• Sector: Healthcare
• Industry: Biotechnology

About: Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.

Employees: 3